Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 698

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 698
---
. The information contained in this proxy
statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies.

455

INDEX TO FINANCIAL STATEMENTS DENALI CAPITAL ACQUISITION CORP.

|                                                                                 |     | Page |      |
| FINANCIAL STATEMENTS:                                                           |     |      |      |
| Report of Independent Registered Public Accounting Firm Marcum Asia CPAs LLP    
 (PCAOB ID Number 5395)                                                          |     |      | F-2  |
| Report of Independent Registered Public Accounting Firm Marcum LLP (PCAOB ID    
 Number 688)                                                                     |     |      | F-4  |
| Consolidated Balance Sheets as of December 31, 2024 and 2023                    |     |      | F-6  |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 
 2023                                                                            |     |      | F-7  |
| Consolidated Statements of Changes in Shareholders’ Deficit for the years       
 ended December 31, 2024 and 2023                                                |     |      | F-8  |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 
 2023                                                                            |     |      | F-9  |
| Notes to Consolidated Financial Statements                                      |     |      | F-10 |
| UNAUDITED CONDENSED FINANCIAL STATEMENTS:                                       |     |      |      |
| Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31,   
 2024                                                                            |     |      | F-35 |
| Consolidated Statements of Operations for the three months ended March 31, 2025 
 and 2024                                                                        |     |      | F-36 |
| Consolidated Statements of Changes in Shareholders’ Deficit for the three       
 months ended March 31, 2025 and 2024                                            |     |      | F-37 |
| Consolidated Statements of Cash Flows for the three months ended March 31, 2025 
 and 2024                                                                        |     |      | F-38 |
| Notes to Unaudited Consolidated Financial Statements                            |     |      | F-39 |

SEMNUR PHARMACEUTICALS, INC.

|                                                                                |     | Page |      |
| FINANCIAL